Skip to main content
Top
Published in: Clinical and Experimental Nephrology 4/2011

01-08-2011 | Original Article

Risk factors for metabolic syndrome in stable Italian renal transplant patients

Authors: Fabio Fabbian, Maurizio Bergami, Christian Molino, Alfredo De Giorgi, Marco Pala, Carlo Longhini, Francesco Portaluppi

Published in: Clinical and Experimental Nephrology | Issue 4/2011

Login to get access

Abstract

Background

The prevalence of metabolic syndrome (MS) in renal transplant recipients (RTR) is still under investigation.

Methods

We performed a cross-sectional study of 107 stable RTR who were diagnosed as having MS defined by the Adult Treatment Panel III of the National Cholesterol Education Program (NCEP-ATP III) criteria. Anthropometric, clinical and biochemical data were collected.

Results

Mean age of the patients studied was 55 ± 11 years (72 male, 35 female), dialysis duration before transplantation 30 ± 31 months, time since transplantation 42 ± 13 months. Mean serum creatinine was 1.68 ± 0.64 mg/dl; creatinine clearance by Cockcroft–Gault formula 53 ± 20 ml/min, glomerular filtration rate by 4-variable MDRD formula 48 ± 18 ml/min/1.73 m2. Thirty-seven patients (34.5%) had MS. The MS patients had higher weight (76 ± 13 vs. 68 ± 12 kg, p = 0.0033), body mass index (BMI) (26 ± 4 vs. 24 ± 3 kg/m2, p = 0.0025), waist circumference (101 ± 11 vs. 90 ± 11 cm, p < 0.0001), prevalence of BMI >25 k/m2 (57 vs. 34%, p = 0.0254), prevalence of diabetes mellitus before transplantation (8 vs. 0%, p = 0.0157), glycaemia (104 ± 31 vs. 87 ± 11 mg/dl, p = 0.0002), and triglyceridaemia (225 ± 105 vs. 112 ± 35 mg/dl, p < 0.0001). They also showed lower levels of high-density lipoprotein cholesterol (48 ± 15 vs. 68 ± 17 mg/dl, p < 0.0001). Multiple logistic regression analysis showed that only BMI was independently associated with MS (OR 1.21, 95% CI 1.06–1.37, p = 0.0037).

Conclusions

MS according to NCEP-ATP III criteria appears to be present in about one-third of RTR, and even small increases in BMI above 25 kg/m2 may determine the presence of MS in these patients. Therefore the preventive value of lifestyle modifications is very important for such patients, in order to strictly maintain body fat accumulation within the normal range.
Literature
1.
go back to reference Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238–45.CrossRefPubMed Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238–45.CrossRefPubMed
2.
go back to reference Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005;293:1861–7.CrossRefPubMed Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005;293:1861–7.CrossRefPubMed
3.
go back to reference Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, Speizer FE, Hennekens CH. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med. 1990;322:882–9.CrossRefPubMed Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, Speizer FE, Hennekens CH. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med. 1990;322:882–9.CrossRefPubMed
4.
go back to reference Lindholm A, Albrechtsen D, Frödin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease − major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation. 1995;60:451–7.CrossRefPubMed Lindholm A, Albrechtsen D, Frödin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease − major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation. 1995;60:451–7.CrossRefPubMed
5.
go back to reference de Mattos AM, Prather J, Olyaei AJ, Shibagaki Y, Keith DS, Mori M, Norman DJ, Becker T. Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. Kidney Int. 2006;70:757–64.CrossRefPubMed de Mattos AM, Prather J, Olyaei AJ, Shibagaki Y, Keith DS, Mori M, Norman DJ, Becker T. Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. Kidney Int. 2006;70:757–64.CrossRefPubMed
7.
go back to reference Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844–50.CrossRefPubMed Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844–50.CrossRefPubMed
8.
go back to reference Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140:167–74.CrossRefPubMed Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140:167–74.CrossRefPubMed
9.
go back to reference Soveri I, Abedini S, Holdaas H, Jardine A, Eriksson N, Fellström B. Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clin Transplant. 2009;23:914–20.CrossRefPubMed Soveri I, Abedini S, Holdaas H, Jardine A, Eriksson N, Fellström B. Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clin Transplant. 2009;23:914–20.CrossRefPubMed
10.
go back to reference Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMed Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMed
11.
go back to reference Levey AS, Greene T, Kusek JW, Beck GL, MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:155A (abstract). Levey AS, Greene T, Kusek JW, Beck GL, MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:155A (abstract).
12.
go back to reference Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed
13.
go back to reference Anonymous. Third Report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421. Anonymous. Third Report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421.
14.
go back to reference Ford ES. Prevalence of metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care. 2005;28:2745–9.CrossRefPubMed Ford ES. Prevalence of metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care. 2005;28:2745–9.CrossRefPubMed
15.
go back to reference Johnson CP, Gallagher-Lepak S, Zhu YR, Porth C, Kelber S, Roza AM, Adams MB. Factors influencing weight gain after renal transplantation. Transplantation. 1993;56:822–7.CrossRefPubMed Johnson CP, Gallagher-Lepak S, Zhu YR, Porth C, Kelber S, Roza AM, Adams MB. Factors influencing weight gain after renal transplantation. Transplantation. 1993;56:822–7.CrossRefPubMed
16.
go back to reference Friedman AN, Miskulin DC, Rosenberg IH, Levey AS. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis. 2003;41:480–7.CrossRefPubMed Friedman AN, Miskulin DC, Rosenberg IH, Levey AS. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis. 2003;41:480–7.CrossRefPubMed
17.
go back to reference Holley JL, Shapiro R, Lopatin WB, Tzakis AG, Hakala TR, Starzl TE. Obesity as a risk factor following cadaveric renal transplantation. Transplantation. 1990;49:387–9.CrossRefPubMedPubMedCentral Holley JL, Shapiro R, Lopatin WB, Tzakis AG, Hakala TR, Starzl TE. Obesity as a risk factor following cadaveric renal transplantation. Transplantation. 1990;49:387–9.CrossRefPubMedPubMedCentral
18.
go back to reference Meier-Kriesche HU, Vaghela M, Thambuganipalle R, Friedman G, Jacobs M, Kaplan B. The effect of body mass index on long-term renal allograft survival. Transplantation. 1999;68:1294–7.CrossRefPubMed Meier-Kriesche HU, Vaghela M, Thambuganipalle R, Friedman G, Jacobs M, Kaplan B. The effect of body mass index on long-term renal allograft survival. Transplantation. 1999;68:1294–7.CrossRefPubMed
19.
go back to reference Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002;73:70–4.CrossRefPubMed Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002;73:70–4.CrossRefPubMed
20.
go back to reference Armstrong KA, Campbella SB, Hawleya CM, Nicolb DL, Johnson DW, Isbela NM. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant. 2005;5:2710–8.CrossRefPubMed Armstrong KA, Campbella SB, Hawleya CM, Nicolb DL, Johnson DW, Isbela NM. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant. 2005;5:2710–8.CrossRefPubMed
21.
go back to reference el-Agroudy AE, Wafa EW, Gheith OE, Shehab el-Dein AB, Ghoneim M. Weight gain after renal transplantation is a risk factor for patient and graft outcome. Transplantation. 2004;77:1381–5.CrossRefPubMed el-Agroudy AE, Wafa EW, Gheith OE, Shehab el-Dein AB, Ghoneim M. Weight gain after renal transplantation is a risk factor for patient and graft outcome. Transplantation. 2004;77:1381–5.CrossRefPubMed
22.
go back to reference Porrini E, Delgado P, Bigo C, Alvarez A, Cobo M, Checa MD, Hortal L, Fernández A, García JJ, Velázquez S, Hernández D, Salido E, Torres A. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis. 2006;48:134–42.CrossRefPubMed Porrini E, Delgado P, Bigo C, Alvarez A, Cobo M, Checa MD, Hortal L, Fernández A, García JJ, Velázquez S, Hernández D, Salido E, Torres A. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis. 2006;48:134–42.CrossRefPubMed
23.
go back to reference de Vries AP, Bakker SJ, van Son WJ, van der Heide JJ, Ploeg RJ, The HT, de Jong PE, Gans RO. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant. 2004;4:1675–83.CrossRefPubMed de Vries AP, Bakker SJ, van Son WJ, van der Heide JJ, Ploeg RJ, The HT, de Jong PE, Gans RO. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant. 2004;4:1675–83.CrossRefPubMed
24.
go back to reference DeFronzo RA, Ferrannini E. Insulin resistance: a multifaced syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–94.CrossRefPubMed DeFronzo RA, Ferrannini E. Insulin resistance: a multifaced syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–94.CrossRefPubMed
25.
go back to reference Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. N Engl J Med. 1995;333:677–85.CrossRefPubMed Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. N Engl J Med. 1995;333:677–85.CrossRefPubMed
26.
go back to reference Rexrode KM, Buing JE, Manson JE. Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord. 2001;25:1047–56.CrossRefPubMed Rexrode KM, Buing JE, Manson JE. Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord. 2001;25:1047–56.CrossRefPubMed
27.
go back to reference Festa A, D’agostino R Jr, Howard G, Mykkanene L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42–7.CrossRefPubMed Festa A, D’agostino R Jr, Howard G, Mykkanene L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42–7.CrossRefPubMed
28.
go back to reference Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM, Isles C, MacFarlane PW, Packard CJ, Cobbe SM, Sheppard J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–9.CrossRefPubMed Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM, Isles C, MacFarlane PW, Packard CJ, Cobbe SM, Sheppard J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–9.CrossRefPubMed
29.
go back to reference Farin HM, Abbassi F, Reaven GM. Comparison of body mass index versus waist circumference with the metabolic changes that increase the risk of cardiovascular disease in insulin-resistant individuals. Am J Cardiol. 2006;98:1053–6.CrossRefPubMed Farin HM, Abbassi F, Reaven GM. Comparison of body mass index versus waist circumference with the metabolic changes that increase the risk of cardiovascular disease in insulin-resistant individuals. Am J Cardiol. 2006;98:1053–6.CrossRefPubMed
30.
go back to reference Meigs JB, Wilson PWF, Fox CS, Vasan RS, Nathan DM, Sullivan LM, D’Agostino RB. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91:2906–12.CrossRefPubMed Meigs JB, Wilson PWF, Fox CS, Vasan RS, Nathan DM, Sullivan LM, D’Agostino RB. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91:2906–12.CrossRefPubMed
Metadata
Title
Risk factors for metabolic syndrome in stable Italian renal transplant patients
Authors
Fabio Fabbian
Maurizio Bergami
Christian Molino
Alfredo De Giorgi
Marco Pala
Carlo Longhini
Francesco Portaluppi
Publication date
01-08-2011
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2011
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0422-4

Other articles of this Issue 4/2011

Clinical and Experimental Nephrology 4/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine